trending Market Intelligence /marketintelligence/en/news-insights/trending/e0bqe_8vxriodrsns-4tkq2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

CTI BioPharma Corp.'s restructuring plan includes 50% employee reduction

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


CTI BioPharma Corp.'s restructuring plan includes 50% employee reduction

CTI BioPharma Corp. will begin a restructuring plan that includes a workforce reduction of 50% across the total number of the company's employees.

The employee reductions will lead to cost savings of an estimated $20 million over three years, according to the company's Dec. 13 press release.

The Seattle-based biopharmaceutical company said the restructuring will improve efficiencies and preserve capital for pacritinib, the company's investigational treatment for myelofibrosis.

Myelofibrosis is a bone marrow disorder that disrupts the body's ability to reproduce red blood cells, according to the Mayo Clinic.

CTI BioPharma will provide financial guidance for the treatment in the first half of 2019 when it determines the details of the U.S. Phase 3 trial design, according to the press release.